Plexxikon announces preclinical data demonstrating dramatic improvement in key symptoms of polycystic kidney disease
BERKELEY, Calif., May 21, 2008 –(BUSINESS WIRE)– Plexxikon Inc. today announced data from preclinical studies of Polycystic Kidney Disease (PKD) demonstrating significantly reduced kidney disease following treatment with Plexxikon’s novel drug candidate. Plexxikon’s novel small molecule kinase inhibitor is a highly selective and potent inhibitor of Raf kinase, a critical mediator of PKD pathology. These data were recently presented at the ISN Forefronts Symposium on Polycystic Kidney Disease in Montreal, Canada by Stefan Somlo, M.D., CNH Long Professor of Internal Medicine and Genetics and Chief of Nephrology at the Yale University School of Medicine.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.